Clearstead Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Clearstead Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$83	–	2576
2025 Q4	$83	Sell	2 -792	-100%	-$31.8K	﹤0.01%	2548
2025 Q3	$30.8K	Sell	794 -1	-0.1%	-$32	﹤0.01%	1454
2025 Q2	$22K	Buy	+795	New	+$20.2K	﹤0.01%	1581

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Clearstead Advisors's KNSA Position: Q1 2026 in Review

Clearstead Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 2 shares — an estimated $83 sold.

Clearstead Advisors first reported a position in KNSA in Q2 2025 and held it in 3 quarters. The position peaked at $30.8K in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Clearstead Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Clearstead Advisors sold 2 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $83.
Clearstead Advisors first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and held it in 3 quarters.
Clearstead Advisors's Kiniksa Pharmaceuticals position peaked at $30.8K in Q3 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.